Travere Therapeutics (TVTX) News Today → Stock-Picking AI Predicts #1 Stock of 2024 (From Altimetry) (Ad) Free TVTX Stock Alerts $6.75 +0.20 (+3.05%) (As of 05/7/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineGossamer Bio: Q1 Earnings Snapshotsfgate.com - May 8 at 3:24 AMBuy Rating Affirmed for Travere Therapeutics on Strong Filspari Sales and Favorable Regulatory Prospectsmarkets.businessinsider.com - May 8 at 3:24 AMTravere Therapeutics (NASDAQ:TVTX) Shares Gap Up After Analyst Upgradeamericanbankingnews.com - May 8 at 1:52 AMAnalysts Offer Insights on Healthcare Companies: Esperion (ESPR) and Travere Therapeutics (TVTX)markets.businessinsider.com - May 7 at 5:23 PMTravere Therapeutics (NASDAQ:TVTX) Stock Rating Reaffirmed by HC Wainwrightmarketbeat.com - May 7 at 2:35 PMTravere Therapeutics (NASDAQ:TVTX) Shares Gap Up Following Analyst Upgrademarketbeat.com - May 7 at 2:19 PMBuy Rating Affirmed for Travere Therapeutics on Robust Drug Sales and Promising Market Expansionmarkets.businessinsider.com - May 7 at 12:22 PMBarclays Reaffirms Their Buy Rating on Travere Therapeutics (TVTX)markets.businessinsider.com - May 7 at 12:22 PMTravere Therapeutics, Inc. (NASDAQ:TVTX) Q1 2024 Earnings Call Transcriptmsn.com - May 7 at 12:22 PMTravere Therapeutics (NASDAQ:TVTX) Price Target Increased to $18.00 by Analysts at Canaccord Genuity Groupmarketbeat.com - May 7 at 11:14 AMTravere Therapeutics (NASDAQ:TVTX) Announces Quarterly Earnings Resultsmarketbeat.com - May 7 at 8:52 AMTravere Therapeutics Inc (TVTX) Q1 2024 Earnings Call Transcript Highlights: Navigating Growth ...finance.yahoo.com - May 7 at 7:21 AMTravere Therapeutics Reports Q1 2024 Results: A Mixed Financial Performance Amidst Strategic ...finance.yahoo.com - May 6 at 9:20 PMTVTX Stock Earnings: Travere Therapeutics Misses EPS, Misses Revenue for Q1 2024msn.com - May 6 at 9:20 PMTravere Therapeutics Reports First Quarter 2024 Financial Resultsfinance.yahoo.com - May 6 at 4:19 PMTravere Therapeutics Reports First Quarter 2024 Financial Resultsglobenewswire.com - May 6 at 4:01 PMTravere Therapeutics Q1 2024 Earnings Previewmsn.com - May 5 at 7:07 PMTravere Therapeutics (TVTX) to Release Quarterly Earnings on Mondayamericanbankingnews.com - May 4 at 2:36 AMTravere Therapeutics (TVTX) Scheduled to Post Earnings on Mondaymarketbeat.com - April 30 at 1:21 PMTravere Therapeutics to Report First Quarter 2024 Financial Resultsglobenewswire.com - April 29 at 4:30 PMTravere Therapeutics, Inc. Expected to Earn FY2025 Earnings of ($1.80) Per Share (NASDAQ:TVTX)marketbeat.com - April 26 at 10:38 AMBuy Rating Affirmed for Travere Therapeutics Following Filspari’s European Approval and Promising US Prospectsmarkets.businessinsider.com - April 26 at 7:50 AMBuy Rating Affirmed for Travere Therapeutics on EU Approval and Promising Revenue Projectionsmarkets.businessinsider.com - April 25 at 7:49 PMTravere Therapeutics, Inc. (NASDAQ:TVTX) Forecasted to Post FY2028 Earnings of $4.29 Per Sharemarketbeat.com - April 25 at 9:13 AMFILSPARI’s European Approval and Market Potential Bolster Buy Rating for Travere Therapeuticsmarkets.businessinsider.com - April 24 at 8:48 PMHC Wainwright Boosts Travere Therapeutics (NASDAQ:TVTX) Price Target to $19.00marketbeat.com - April 24 at 3:53 PMTravere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathyglobenewswire.com - April 24 at 7:05 AMCSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathyprnewswire.com - April 24 at 3:00 AMVontobel Holding Ltd. Purchases Shares of 287,423 Travere Therapeutics, Inc. (NASDAQ:TVTX)marketbeat.com - April 19 at 5:37 AMTravere Therapeutics (NASDAQ:TVTX) Earns "Outperform" Rating from Wedbushmarketbeat.com - April 17 at 3:51 PMTravere Therapeutics CFO sells shares to cover tax obligationsinvesting.com - April 14 at 12:58 AMVanguard Group Inc. Acquires 460,176 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)marketbeat.com - April 10 at 4:00 AMStock market today: Stocks slide after Fedspeak as oil surges, March jobs report on decknz.finance.yahoo.com - April 4 at 8:02 PMTravere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians Internationalglobenewswire.com - April 4 at 4:30 PMTravere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Associationglobenewswire.com - April 3 at 4:30 PMTravere Therapeutics (NASDAQ:TVTX) Trading Down 6%marketbeat.com - April 1 at 4:50 PMTravere Therapeutics (NASDAQ:TVTX) Shares Gap Down to $7.57marketbeat.com - March 27 at 12:23 PMTravere Therapeutics (NASDAQ:TVTX) Receives "Neutral" Rating from Guggenheimmarketbeat.com - March 27 at 8:18 AMTravere Therapeutics (NASDAQ:TVTX) Trading 7.5% Higher marketbeat.com - March 21 at 5:42 PMTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com - March 13 at 5:00 PMBuy Rating Affirmed for Travere Therapeutics on Strong FILSPARI Data and Favorable Regulatory Outlookmarkets.businessinsider.com - March 13 at 2:22 PMPeeling Back The Layers: Exploring Travere Therapeutics Through Analyst Insightsmarkets.businessinsider.com - March 13 at 2:22 PMTravere Therapeutics (NASDAQ:TVTX) Trading 6.1% Higher marketbeat.com - March 13 at 1:51 PMJacobs Levy Equity Management Inc. Boosts Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)marketbeat.com - March 12 at 8:39 AMTravere Therapeutics Submits SNDA Seeking Full Approval Of Filspari In IgA Nephropathymarkets.businessinsider.com - March 11 at 7:50 AMTravere Therapeutics Submits SNDA Seeking Full Approval Of Filspari In IgA Nephropathymarkets.businessinsider.com - March 11 at 7:50 AMTravere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)globenewswire.com - March 11 at 7:05 AMSchonfeld Strategic Advisors LLC Has $4.69 Million Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)marketbeat.com - March 5 at 9:30 AMTravere Therapeutics, Inc. (NASDAQ:TVTX) Given Average Recommendation of "Moderate Buy" by Analystsmarketbeat.com - March 5 at 1:34 AMAnalysts Have Conflicting Sentiments on These Healthcare Companies: Moderna (MRNA) and Travere Therapeutics (TVTX)markets.businessinsider.com - February 28 at 4:43 AM Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address The #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique Way (Ad)See how with its ongoing expansion and development of its diverse and promising product pipeline, this small-cap NYSE company is positioned to be a dominant and innovative leader in the nanomedicine and antiviral therapy space. Click to read TVTX Media Mentions By Week TVTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TVTX News Sentiment▼-0.310.38▲Average Medical News Sentiment TVTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TVTX Articles This Week▼183▲TVTX Articles Average Week Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: KalVista Pharmaceuticals News Today Altimmune News Today Oculis News Today Shattuck Labs News Today Verve Therapeutics News Today Larimar Therapeutics News Today Adlai Nortye News Today COMPASS Pathways News Today Arbutus Biopharma News Today Astria Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TVTX) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersShocking: One AI startup's revenue could surge 4,735%Manward PressConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorStock-Picking AI Predicts #1 Stock of 2024Altimetry[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsElon Musk Secret Crypto Plot ExposedCrypto 101 MediaAI “wealth window” is closing June 25thParadigm PressThe #1 lithium battery stock to have on your radar in 2024!Smallcaps Daily Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
